Evidence map›Paper›PMID 39462373›Full record

ArticleBMC veterinary research2024

Treatment with oclacitinib, a Janus kinase inhibitor, down-regulates and up-regulates CD25 and Foxp3 expression, respectively, in peripheral blood T cells of dogs with atopic dermatitis.

Agnieszka Jasiecka-Mikołajczyk, Piotr Socha

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC veterinary research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Agnieszka Jasiecka-MikołajczykDepartment of Pharmacology and Toxicology, Faculty of Veterinary Medicine, University of Warmia and Mazury, Oczapowskiego 13, Olsztyn, 10-719, Poland. agnieszka.jasiecka@uwm.edu.pl.
Piotr SochaDepartment of Animal Reproduction with Clinic, Faculty of Veterinary Medicine, University of Warmia and Mazury in Olsztyn, Oczapowskiego 14, 10-719, Olsztyn, Poland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundOclacitinib (OCL), a Janus kinase inhibitor, is a novel immunomodulatory/immunosuppressive agent which is an approved as the first-line treatment for atopic dermatitis (AD) in dogs. The aim of the study was to investigate the effects of OCL on CD4

resultsThe study showed that the mean percentage and absolute count of CD4

conclusionsThe findings of the study strongly suggest that: (a) in terms of the impact of OCL on the number of PB CD4

Indexed as

CD4-Positive T-LymphocytesCD8-Positive T-LymphocytesDermatitis, AtopicDog DiseasesDown-RegulationForkhead Transcription FactorsInterleukin-2 Receptor alpha SubunitPyrimidinesSulfonamidesAnimalsDogsFemaleJanus Kinase InhibitorsMaleUp-RegulationForkhead Transcription FactorsInterleukin-2 Receptor alpha SubunitJanus Kinase InhibitorsoclacitinibPyrimidinesSulfonamidesAtopic dermatitisCD4+ cellsCD8+ cellsDogsOclacitinibTreg cells

Identifiers

PMID39462373
PMCPMC11515184

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.